VIA
FDMT icon

Virtus Investment Advisers’s 4D Molecular Therapeutics FDMT Stock Holding History

Virtus Investment Advisers’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$493K Buy
37,055
+11,901
+47% +$116K 0.11% 211
2026
Q1 		$234K Buy
25,154
+613
+2% +$5.33K 0.06% 321
2025
Q4 		$184K Buy
+24,541
New +$249K 0.05% 369
2025
Q2 		– Sell
-23,864
Closed -$77.1K – 460
2025
Q1 		$77.1K Buy
+23,864
New +$112K 0.02% 450

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Virtus Investment Advisers's FDMT Position: Q2 2026 in Review

Virtus Investment Advisers increased its 4D Molecular Therapeutics (FDMT) stake by 47% in Q2 2026, buying an estimated $116K and bringing the position to 37,055 shares worth $493K. The position accounts for 0.11% of the portfolio, ranked #211.

Virtus Investment Advisers first reported a position in FDMT in Q1 2025 and has held it in 4 quarters since. 157 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Virtus Investment Advisers held 37,055 shares of 4D Molecular Therapeutics worth $493K as of Q2 2026.
  • Virtus Investment Advisers bought 11,901 4D Molecular Therapeutics shares in Q2 2026, an estimated $116K.
  • 4D Molecular Therapeutics made up 0.11% of Virtus Investment Advisers's portfolio in Q2 2026, its #211 holding.
  • Virtus Investment Advisers first reported a position in 4D Molecular Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • 157 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.